About Circularis
Circularis is a Healthcare company based in Davis (United States) founded in 2004, and was acquired by Ginkgo Bioworks in October 2022. Tool to tune in-vivo to protein production. Circularis has raised $250 thousand across 1 funding round from investors including Ginkgo Bioworks and IndieBio. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its competitors include Avidity Biosciences, Poseida Therapeutics and Senti Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Circularis was founded in 2004 in Davis, United States, within the biotechnology sector. Operations center on a platform that identifies DNA promoters regulating genome expression across organisms and cell types in a single step. Promoter activity is measured, and new switches are evolved or synthesized to suit applications. This supports enhancements in bioreactor yields, specialty crop engineering, cancer therapeutics, and related fields.
- Headquarters Davis, United States
- Stage Acquired
- SectorsHealthcare
- Website circularisbiotech.com
- Social LinkedIn X
- Acquired by Ginkgo Bioworks (Oct 2022)
- Total Equity Funding$250K (USD)
in 1 rounds
- Latest Funding Round$250K (USD), Seed
Oct 2015
- InvestorsGinkgo Bioworks
& 1 more
- Acquired byGinkgo Bioworks
(Oct 2022)
Funding Insights of Circularis
Circularis has successfully raised a total of $250K through 1 strategic funding round. The most recent funding activity was a Seed round of $250 thousand completed in October 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $250,000
- Total Rounds 1
- Last Round Seed — $250,000
- First Round $250,000
(Oct 2015)
- Investors Count 1
All 1 funding rounds of Circularis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2015 | $250,000 | Seed | – | IndieBio | – |
2 investors in total: 2 institutional.
Investors in Circularis
Circularis has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Ginkgo Bioworks and IndieBio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biotech startups are accelerated through IndieBio's focused programs. | indiebio.co | San Francisco, United States | ||
Gene editing-based cultured ingredients are provided for agriculture. | 2008 | ginkgobioworks.com | Boston, United States |
Investor details for Circularis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Circularis
235 people are tracked at Circularis (78 in leadership, 7 in board & advisors, 150 in team).
| Name | Role | Group |
|---|---|---|
Adam Bargar | Director, Program Finance | Leadership |
Michael Mashock | Associate Director, Lab Enablement | Leadership |
Michael Torrens-Spence | Associate Technical Director, Microbial Engineering (soe2) | Leadership |
Arthur Fong III | Associate Director, Business Operations And Strategy | Leadership |
Kent Wilson | Associate Director Business Development | Leadership |
Cornelis Mijnders | VP, Business Development | Leadership |
Kevin Wright | VP, Continuous Improvement & Industrial Engineering | Leadership |
Dominik Satory | Director, Microbial Engineering | Leadership |
Ryan McCann | Head Of Microbiology | Leadership |
Ariel Hecht | Director Of Microbial Assay Development | Leadership |
Kendrick Goss | Director, Senior Mammalian Engineer III | Leadership |
Swaminath Srinivas | Director - Organism Engineering | Leadership |
Katie Vinter | Associate Director, Project Engineering | Leadership |
Philip Merksamer | Vp, Commercial Transactions & Business Development | Leadership |
Prabha Ramakrishnan | Senior Director, Business Development | Leadership |
Sean Morrison | Director, Revenue Accounting & Operations | Leadership |
Alex Tucker | Senior Director, Business Development And Alliance Management | Leadership |
Philipp Heuermann | Director - Business Development, Ginkgo Datapoints | Leadership |
Kunal Mehta | Director Of Business Development | Leadership |
Narendra Maheshri | Vp, Head Of Mammalian Engineering | Leadership |
215 more people are available in the full profile.
Complete people profiles for Circularis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Circularis
3 dated milestones of Circularis across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Circularis is founded.
- Funding First funding round of $250K.
- Exit Acquired by Ginkgo Bioworks.
Competitors of Circularis
Circularis has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Poseida Therapeutics and Senti Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| sentibio.com | 2016 | San Francisco, United States | $158M | Cell-based therapies for cancer treatment are developed. |
Detailed competitors of Circularis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Circularis (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Circularis
Complete news archive for Circularis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Circularis
Circularis was founded in 2004 and raised its 1st funding round 11 years after it was founded.
Circularis is headquartered in Davis, United States. It is registered at Davis, California, United States.
Circularis is a funded company, having raised a total of $250K across 1 funding round to date. The company's 1st funding round was a Seed of $250K, raised on Oct 2015.
Circularis was founded in 2004 in Davis, United States, within the biotechnology sector. Operations center on a platform that identifies DNA promoters regulating genome expression across organisms and cell types in a single step. Promoter activity is measured, and new switches are evolved or synthesized to suit applications. This supports enhancements in bioreactor yields, specialty crop engineering, cancer therapeutics, and related fields.
Circularis's top competitors include Avidity Biosciences, Senti Biosciences and Poseida Therapeutics.
Circularis has 2 investors. Key investors include Ginkgo Bioworks, and IndieBio.
Yes. Circularis was acquired by Ginkgo Bioworks in October 2022.